A Study Testing the Safety and Effects of FB102 in Healthy Volunteers

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 14% 56 → 48 participants
See other at-risk trials from Forte Biosciences, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 48 → 64 participants Show 5 more changesShow less
    • Study completion pushed from Feb 2027 to Jun 2027
    • Interventions modified
    • Trial arms changed: 3 → 4
    • Eligibility criteria expanded, about 11 words
    • Study description expanded, about 54 words
  2. Recruitment opened
    • Enrollment reduced: 56 → 48 participants
    • Study sites: 1 to 2
    • Start date changed from estimate of Jun 2026 to Jun 23, 2026
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this Phase 1 trial is to evaluate the safety and effects of FB-102 in healthy volunteers following single and multiple doses.
Trial Details
NCT Number NCT07623057
Lead Sponsor Forte Biosciences, Inc.
Conditions
(from sponsor)		 Healthy Volunteer
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov